Merck Serono Acquires Multiple Sclerosis Drug; Nixon Peabody Legal Team Advises on Deal
October 14, 2011 // Franchising.com // Boston, MA. Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has acquired the worldwide exclusive development and commercialization rights to PI-2301, an experimental drug for multiple sclerosis.
PI-2301 is a second-generation peptide copolymer that is thought to enhance the regulatory response of the immune system and dampen immune responses that drive autoimmune diseases such as multiple sclerosis. Merck will evaluate the product for autoimmune diseases including multiple sclerosis. The drug was originally developed by Peptimmune, the Cambridge, MA–based peptide therapeutics firm.
Nixon Peabody LLP served as Merck Serono’s legal counsel. The team was led by global business & transactions and life sciences partner Chris Keefe and bankruptcy & financial restructuring practice group leader Victor Milione. Patents group partner Mark FitzGerald also worked on the deal.
###
Comments:
comments powered by Disqus
| ADVERTISE | SPONSORED CONTENT |
| ADVERTISE | SPONSORED CONTENT |
Franchising.com is produced by Franchise Update Media. Franchise Update Media has its finger on the pulse of franchising with unrivalled audience intelligence and market driven data. No media company understands the franchise landscape deeper than Franchise Update Media.
P.O. Box 20547
San Jose, CA 95160
PH. (408) 402-5681
The franchise opportunities listed above are not related to or endorsed by Franchising.com or Franchise Update Media Group. We are not engaged in, supporting, or endorsing any specific franchise, business opportunity, company or individual. No statement in this site is to be construed as a recommendation. We encourage prospective franchise buyers to perform extensive due diligence when considering a franchise opportunity.
Copyright © 2001 - 2024. All Rights Reserved. Legal Notices | Privacy Policy